Grith Lykke Sørensen

Curriculum Vitae, Grith Lykke Sørensen

Education and academic qualifications

1995B.Sc. from University of Roskilde in molecular biology and chemistry

1998M.Sc. from University of Copenhagen in human biology (grade: 11.2)

1998Ph.D.-position at University of Southern Denmark, Odense University, The Faculty of Science and Engineering

2000Change of Ph.D-project, now at Immunology and Microbiology, SDU, Odense University

2000Stay at Sct. Radcliffe Hospital in Oxford in Dr. Zsuzsa Kertesz laboratory

2003PhD from the University of Southern Denmark (5/12-2003)

2017Doctor of Medical Sciences (DMSci) from the University of Southern Denmark (29/9-2017)

Employment

2003Assistant professor at Institute of Medical Biology (IMB), University of Southern Denmark

2003Maternal leave (December 2003 – July 2004)

2007Maternal leave (March 2007 – October 2007)

2007Assistant professor position at Medical Biotechnology Center, MBC, University of Southern Denmark

2009Associate professor position at Cardiovascular and Renal Research,Department of Molecular Medicine, University of Southern Denmark

2014Associate professor position at Cancer and Inflammation, Department of Molecular Medicine, University of Southern Denmark 

2016    Sick leave (2/11-2016 – 6/6-2017)

2018    Professor MSO position Cancer and Inflammation research, IMM, SDU

Other scientific qualifications

• >30 international meetings with oral or poster presentation
• Chairman of three PhD-defenses, member of assessment committee of 5 Ph.D.-defenses in DK and UK
• 2015  Member of editorial board of Frontiers in Immunology; Molecular Innate Immunity.
• 2018  Member of assessment committee for South-Eastern Norway regional health authority’s (Helse Sør-Øst RHF) funding of research projects
• Innovation:Co-inventor of four patents, and cofounder of Biolectin in 2000. Main driver of a study of anti-MFAP4 antibodies as a new drug for treatment of age-related macula degeneration (AMD) and diabetic macular edema. GLS has recieved SDU Proof-of-Concept grant 2013 and Novo Nordisk Pre-Seed grant 2015 for this project. GLS recieved 2.278.000 € from The Danish Innovation Foundation and 406.000 € in SDU co-financing for the same project in 2017.

Academic award

2018    Innovationsprisen, SDU

Management experience

2011    Completion of Research Leader and Management Course at the Copenhagen Business School 2010-2018 Project leader for Center for COPD research CeKOL (www.cekol.dk) funded by the Danish Strategic Research Council

2017-> Project leader for the DARE project under investment from Innovation Fund Denmark

2018 - 2019   INSEAD Research leader course, Copenhagen/Paris Fontaine Bleu

Supervision

Main supervisor for 1 previous and 1 current post doc, 7 graduated and 4 current Ph.D.-students.

Co-supervisor for 12 previous and 2 current Ph.D.-students.

Major Grants 2010 - 2018

The Danish Strategic Research Council (Center-application; total of 2.4 mio €) 2010: 570.000 €

Region Syddanmarks PhD-fund 2010 : 71.000 €

The Lundbeck Foundation 2011: 107.000 €

The Lundbeck Foundation 2012: 80.000 €

The Lundbeck Foundation 2014: 214.000 €

Novo Nordisk Pre-Seed grant (Collaboration; total of 357.000 €) 2015: 143.000 €

Øjenfonden 2016: 40.000 €

Novo Nordisk endocrinology research and experimental physiology grant 2016: 40.000 €

The Danish Research Council grant 2017: 350.000 €

Novo Nordisk endocrinology and metabolism grant 2017: 180.000 €

The Danish Innovation Foundation 2017: 2.278.000€; SDU co-financing: 406.000 €

Novo Nordisk Bioscience and Basic Biomedicine 2017/2018: 160.000 €